In vitro immunoglobulin production by mononuclear cells in rheumatoid arthritis

Richard S. Panush, Paul Katz, Selden Longley

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Since patients with rheumatoid arthritis (RA) exhibit serum hypergammaglobulinemia and autoantibody (rheumatoid factor) production, we compared elaboration and control of in vitro RA mononuclear cell (MNC), Ig assayed by enzyme-linked immunoassays or by hemolytic plaque formation, in 37 RA patients and 17 normal subjects. We found (1) RA spontaneous plaque-forming cells were significantly reduced (RA 344 vs normal 627 PFC 106 MNC, P < 0.002); (2) RA spontaneous IgG and IgM (but not IgA) elaboration was significantly diminished (IgG RA 339, normal 776; IgM RA 255, normal 869 ng/ml, P < 0.001; IgA RA 87, normal 124); (3) RA stimulated IgG and IgM production (but not IgA) was also decreased (IgG RA 2434, normal 3862, P < 0.06; IgM RA, 1676, normal 3323, P < 0.005; IgA RA 1859, normal 2315); (4) reduced RA Ig elaboration was not clearly due to altered numbers of T or non-T cells, age, medications, clinical features of disease, or response kinetics; (5) relative improvement of RA in vitro IgG, but not usually IgM, secretion followed removal of adherent cells, addition of indomethacin or addition of mitomycin C-treated T cells; (6) MNC from synovial fluids, but not bone marrows, exhibited spontaneous Ig production in excess of stimulated synovial fluid cellular or peripheral blood Ig elaboration. These observations indicate selective impairment of peripheral blood MNC IgG and, particularly, IgM secretion in RA. This defect appears to reflect accessory cell influences which differ from normal as well as the sequestration of primed or activated cells in the synovial fluid.

Original languageEnglish
Pages (from-to)252-264
Number of pages13
JournalClinical Immunology and Immunopathology
Volume28
Issue number2
DOIs
StatePublished - Jan 1 1983
Externally publishedYes

Fingerprint

Immunoglobulins
Rheumatoid Arthritis
Immunoglobulin M
Immunoglobulin G
Immunoglobulin A
Synovial Fluid
In Vitro Techniques
Hypergammaglobulinemia
Rheumatoid Factor
Mitomycin
Immunoenzyme Techniques
Indomethacin
Autoantibodies
Blood Cells
Bone Marrow

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pathology and Forensic Medicine

Cite this

In vitro immunoglobulin production by mononuclear cells in rheumatoid arthritis. / Panush, Richard S.; Katz, Paul; Longley, Selden.

In: Clinical Immunology and Immunopathology, Vol. 28, No. 2, 01.01.1983, p. 252-264.

Research output: Contribution to journalArticle

Panush, Richard S. ; Katz, Paul ; Longley, Selden. / In vitro immunoglobulin production by mononuclear cells in rheumatoid arthritis. In: Clinical Immunology and Immunopathology. 1983 ; Vol. 28, No. 2. pp. 252-264.
@article{87d3e50f0e474c8680ebb1606993e6db,
title = "In vitro immunoglobulin production by mononuclear cells in rheumatoid arthritis",
abstract = "Since patients with rheumatoid arthritis (RA) exhibit serum hypergammaglobulinemia and autoantibody (rheumatoid factor) production, we compared elaboration and control of in vitro RA mononuclear cell (MNC), Ig assayed by enzyme-linked immunoassays or by hemolytic plaque formation, in 37 RA patients and 17 normal subjects. We found (1) RA spontaneous plaque-forming cells were significantly reduced (RA 344 vs normal 627 PFC 106 MNC, P < 0.002); (2) RA spontaneous IgG and IgM (but not IgA) elaboration was significantly diminished (IgG RA 339, normal 776; IgM RA 255, normal 869 ng/ml, P < 0.001; IgA RA 87, normal 124); (3) RA stimulated IgG and IgM production (but not IgA) was also decreased (IgG RA 2434, normal 3862, P < 0.06; IgM RA, 1676, normal 3323, P < 0.005; IgA RA 1859, normal 2315); (4) reduced RA Ig elaboration was not clearly due to altered numbers of T or non-T cells, age, medications, clinical features of disease, or response kinetics; (5) relative improvement of RA in vitro IgG, but not usually IgM, secretion followed removal of adherent cells, addition of indomethacin or addition of mitomycin C-treated T cells; (6) MNC from synovial fluids, but not bone marrows, exhibited spontaneous Ig production in excess of stimulated synovial fluid cellular or peripheral blood Ig elaboration. These observations indicate selective impairment of peripheral blood MNC IgG and, particularly, IgM secretion in RA. This defect appears to reflect accessory cell influences which differ from normal as well as the sequestration of primed or activated cells in the synovial fluid.",
author = "Panush, {Richard S.} and Paul Katz and Selden Longley",
year = "1983",
month = "1",
day = "1",
doi = "10.1016/0090-1229(83)90159-9",
language = "English",
volume = "28",
pages = "252--264",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - In vitro immunoglobulin production by mononuclear cells in rheumatoid arthritis

AU - Panush, Richard S.

AU - Katz, Paul

AU - Longley, Selden

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Since patients with rheumatoid arthritis (RA) exhibit serum hypergammaglobulinemia and autoantibody (rheumatoid factor) production, we compared elaboration and control of in vitro RA mononuclear cell (MNC), Ig assayed by enzyme-linked immunoassays or by hemolytic plaque formation, in 37 RA patients and 17 normal subjects. We found (1) RA spontaneous plaque-forming cells were significantly reduced (RA 344 vs normal 627 PFC 106 MNC, P < 0.002); (2) RA spontaneous IgG and IgM (but not IgA) elaboration was significantly diminished (IgG RA 339, normal 776; IgM RA 255, normal 869 ng/ml, P < 0.001; IgA RA 87, normal 124); (3) RA stimulated IgG and IgM production (but not IgA) was also decreased (IgG RA 2434, normal 3862, P < 0.06; IgM RA, 1676, normal 3323, P < 0.005; IgA RA 1859, normal 2315); (4) reduced RA Ig elaboration was not clearly due to altered numbers of T or non-T cells, age, medications, clinical features of disease, or response kinetics; (5) relative improvement of RA in vitro IgG, but not usually IgM, secretion followed removal of adherent cells, addition of indomethacin or addition of mitomycin C-treated T cells; (6) MNC from synovial fluids, but not bone marrows, exhibited spontaneous Ig production in excess of stimulated synovial fluid cellular or peripheral blood Ig elaboration. These observations indicate selective impairment of peripheral blood MNC IgG and, particularly, IgM secretion in RA. This defect appears to reflect accessory cell influences which differ from normal as well as the sequestration of primed or activated cells in the synovial fluid.

AB - Since patients with rheumatoid arthritis (RA) exhibit serum hypergammaglobulinemia and autoantibody (rheumatoid factor) production, we compared elaboration and control of in vitro RA mononuclear cell (MNC), Ig assayed by enzyme-linked immunoassays or by hemolytic plaque formation, in 37 RA patients and 17 normal subjects. We found (1) RA spontaneous plaque-forming cells were significantly reduced (RA 344 vs normal 627 PFC 106 MNC, P < 0.002); (2) RA spontaneous IgG and IgM (but not IgA) elaboration was significantly diminished (IgG RA 339, normal 776; IgM RA 255, normal 869 ng/ml, P < 0.001; IgA RA 87, normal 124); (3) RA stimulated IgG and IgM production (but not IgA) was also decreased (IgG RA 2434, normal 3862, P < 0.06; IgM RA, 1676, normal 3323, P < 0.005; IgA RA 1859, normal 2315); (4) reduced RA Ig elaboration was not clearly due to altered numbers of T or non-T cells, age, medications, clinical features of disease, or response kinetics; (5) relative improvement of RA in vitro IgG, but not usually IgM, secretion followed removal of adherent cells, addition of indomethacin or addition of mitomycin C-treated T cells; (6) MNC from synovial fluids, but not bone marrows, exhibited spontaneous Ig production in excess of stimulated synovial fluid cellular or peripheral blood Ig elaboration. These observations indicate selective impairment of peripheral blood MNC IgG and, particularly, IgM secretion in RA. This defect appears to reflect accessory cell influences which differ from normal as well as the sequestration of primed or activated cells in the synovial fluid.

UR - http://www.scopus.com/inward/record.url?scp=0020535880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020535880&partnerID=8YFLogxK

U2 - 10.1016/0090-1229(83)90159-9

DO - 10.1016/0090-1229(83)90159-9

M3 - Article

C2 - 6347489

AN - SCOPUS:0020535880

VL - 28

SP - 252

EP - 264

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -